Kareem Reda

Founder, Cumulus Therapeutics

Kareem is the founder of Cumulus Therapeutics, a company dedicated to building fast follower biologics for critical disease in autoimmune and inflammation space. The company last year established a partnership with FairJourney Bio, a $1B privately held antibody discovery and development biotech in Portugal, to establish their first three assets through initial preclinical proof of concept.  He is also on the board of George Church spinout 64x Bio and advises several companies on strategy, capital formation, and partnerships.

He was most recently Chief Business Officer at Elevate Bio where he led and executed multiple strategic long-term partnerships for the company including collaborations with Moderna and Novo Nordisk and helped the company raise >$1B in equity financing during his tenure. Prior to joining ElevateBio, Mr. Reda was the Head of Business Development and Corporate Strategy at Evelo Biosciences. While there, he played an integral role in the company’s $85 million initial public offering (IPO) and private Series B and C fundraising rounds, helping to raise over $200 million. Mr. Reda previously worked at Celgene in business development where he executed over a dozen deals with a total value greater than $5 billion. Notably, Mr. Reda led the B-cell maturation antigen (BCMA) collaboration with bluebird bio and the $1 billion, 10-year collaboration with Juno Therapeutics. He started his career at Vertex Pharmaceuticals. In his career he has played a role in the development or acquisition of 6 FDA approved therapies. 

Mr. Reda graduated magna cum laude with honors as a Chemical Engineer from Brown University and received his MBA from Harvard Business School.